News
ARQT
24.17
+1.05%
0.25
Arcutis Biotherapeutics: An Emerging GARP Stock
Seeking Alpha · 2d ago
Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)
Seeking Alpha · 2d ago
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Barchart · 2d ago
Weekly Report: what happened at ARQT last week (0928-1002)?
Weekly Report · 3d ago
Arcutis Biotherapeutics partners with Simone Biles for new awareness campaign
TipRanks · 09/29 13:20
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
Barchart · 09/29 08:15
Weekly Report: what happened at ARQT last week (0921-0925)?
Weekly Report · 09/28 10:04
3 Healthcare ETFs for FDA-Approved Profits
Barchart · 09/23 10:15
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
NASDAQ · 09/21 11:33
Weekly Report: what happened at ARQT last week (0914-0918)?
Weekly Report · 09/21 10:04
Guidance Reaffirmed Might Change The Case For Investing In Arcutis Biotherapeutics (ARQT)
Simply Wall St · 09/18 14:31
Arcutis Biotherapeutics falls -5.1%
TipRanks · 09/17 16:05
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
NASDAQ · 09/17 14:38
Arcutis Biotherapeutics rises 7.7%
TipRanks · 09/16 14:05
Weekly Report: what happened at ARQT last week (0907-0911)?
Weekly Report · 09/14 10:09
Weekly Report: what happened at ARQT last week (0831-0904)?
Weekly Report · 09/07 10:03
The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
Seeking Alpha · 09/06 13:15
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added
Seeking Alpha · 09/04 22:20
S&P 600 adding ten companies at open on 9/21
TipRanks · 09/04 21:50
Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 09/04 20:00
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.